Basic Sciences, Clinical Medicine

Drug Development: Molecular Targets for GI Diseases

Name: Drug Development: Molecular Targets for GI Diseases
Author: Timothy S. Gaginella
ISBN: 9781617370878

by Timothy S. Gaginella (Editor), Antonio Guglietta (Editor)

Available on Bookshop Write a review

Books.org participates in affiliate programs including Bookshop.org and the Amazon Services LLC Associates Program. We may earn a commission from qualifying purchases made through links on this page, at no additional cost to you.

Overview

Timothy Gaginella and Antonio Guglietta bring together hands-on experts to critically review the many promising new areas of gastrointestinal pharmacology at the molecular level. Key chapters discuss such major themes as cyclooxygenase-2 inhibitors, the complexities of nitric oxide pathways in the gut, and the influence of cytokines on inflammatory bowel disease, as well as new opportunities for pharmacotherapy, including peptide growth factors, achykinins-particularly substance P and neurokinins-cholecystokinin receptors, and serotonin. Also examined as possible sites for treating motility disorders and visceral pain are the opioid receptors residing in the gut, and the H3-receptor agonists for treating gut inflammation and pain. Drug Development: Molecular Targets for Gastrointestinal Disease provides a comprehensive review of today's molecular pharmacological approaches to the discovery and development of novel drugs for gastrointestinal and liver diseases.

The book contains black-and-white illustrations.

Synopsis

The application of molecular techniques to gastroenterology continues to yield important advances in the development of drugs to treat gastrointestinal disorders. Important new drugs have emerged through the collaborative and complementary efforts of basic scientists, clinicians, and clinical researchers in academia and the pharmaceutical industry. The challenge has been exciting, with a few surprises along the way. Consider peptic ulcer disease as an example. The discovery of H receptors and the availability of potent and 2 selective H-receptor antagonists signaled the beginning of a new era 2 in the treatment of gastric hypersecretory states and peptic ulcers. Introduction of proton pump inhibitors offered another therapeutic option. Though H-receptor antagonists and proton pump inhibitors 2 are important and useful drugs, the discovery of the link between H. pylori infection and peptic ulcer disease has led to even more effective pharmacotherapeutic regimens. Our intent in Drug Development: Molecular Targets for GI Diseases is to bring together hands-on experts to review promising areas of gastrointestinal pharmacology. The contemporary topics covered, from a mechanistic viewpoint, are relevant to gastrointestinal inflammation and motility disorders. Authoritative opinions are offered on both future research directions and potential applications for new therapies.

Reviews

There are no reviews yet. Log in to write one.

Editorials

Booknews

Reviews the latest research in promising areas of gastrointestinal pharmacology at the molecular level. Chapters discuss major themes including cyclooxygenase-2 inhibitors, nitric oxide pathways in the gut, influences of cytokines on inflammatory bowel disease, and new opportunities for pharmacotherapy, including peptide growth factors and serotonin. Also examined are potentials of opioid receptors in the gut as possible sites for treating motility disorders and visceral pain, and H3-receptor agonists for treating gut inflammation and pain. Gaginella is affiliated with the school of pharmacy at the University of Wisconsin-Madison. Guglietta is affiliated with Parke-Davis Pharmaceutical Research Division. Annotation c. Book News, Inc., Portland, OR (booknews.com)